Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSL Of Australia Begins First Clinical Trials For H1N1 Flu Vaccine

This article was originally published in PharmAsia News

Executive Summary

Australia's CSL said human clinical trials have begun for its H1N1 flu virus, the first test to last seven weeks. The first batches are earmarked for Australia, Singapore and the United States, all of which have placed orders. French drug maker Sanofi-Aventis, as well as the World Health Organization, are expected to keep a close eye on the CSL trials for indications of how other H1N1 vaccine candidates might perform. An analyst noted there is little commercial advantage for a company to be the first in clinical trials for this vaccine, since so many governments have orders with several companies. (Click here for more

You may also be interested in...



Deals Shaping The Medical Industry, February 2020

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.

2020 Could Spell The End Of Mega-Mergers, For Now

Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.

Creating Stability In A Time Of Transition

UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.

UsernamePublicRestriction

Register

SC072249

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel